30 Outcome mean (SD) 42.7 (1.1) I:43.4 (12.4), II:42.5 (6.2), p=0.817 Post-Tx: 92.6 (18) I:90, II:94, III:94, IV:89, p>0.05 97.4 (11.2) 72 (SE 2) I:79 (SE 3), II:70 (SE 5), III:59 (SE 5), KW p=0.002, MW p=0.11 2y: 66.2 (SE 2.8) 10y: 71.2 (SE 2.8) p=0.08 I:79 (SE 7.3), II:43.5 (SE 4.8), p<0.001 I:86.7 (22.9), II:56.7 (30.0), MW p=0.041 N/A Timing of assessment in m (range) (12-84) (13-108) 24 28.7 (6-80.4) 6 (4.5-9.0) 12 (9.0-18.0) >18 med.25 (IQR 20-28) med. 121 (IQR 117-124) 45 (14-65) med. 34 I:31.7 (SD 7.8) II:38.0 (SD 5.9) 41.5 Treatment (n) Res., ALTFF rec., PO(C)RT (33) Res., rec., PO(C)RT (I:7, II:8) HG, RFFF rec., marginal mandible rec. (9), SND(43), MRND(4), adj. RT(I:5, II:24, III:9) Res., ND (14) Mandibular res. (II:44, III:57), soft tissue FF (I:74, II:37), composite FF rec. (III:57), adj. RT (I:35, II:16, III:29) Res.(166), res. with RT(59), only RT(5), rec. with composite FF(45) or soft FF(103) Unilateral extended SOND (I:3, II:7), bilateral extended SOND(II:12), FPND (I:1, II:7), PORT (26) Sentinel lymph node biopsy (I:15), cervical ND level IIII(II:9), adj. RT (I:1, II:6), concurrent CRT(II:1) Segm. mandibulectomy, myocutaneous flap (72%), FF rec. (28%), PORT (42), POCRT (3) N stage (n) N0: 38 N1: 8 N2: 4 N3: 1 N/A N/A Unknown N: 11, N0: 26, N1: 1, N2: 1 N/A N/A N0: I:9, II:8 N1: I:1, II:10 N2: I:0, II:8 N0: I:15, II:4 N+: II:5 N0: 26 N1: 9 N2: 10 N3: 2 T stage (n) T1: 3 T2: 16 T3: 24 T4: 8 T1-2: I:8, II:10 T3-4: I:9, II:14 T2:13 T3: 23 T4: 11 Tis: 11 T1: 24 T2: 4 T1-4: 224 N/A T1: I:6, II:4 T2: I:4, II:22 T1: I:14, II:2 T2: I:1, II:5 T3: II:1 T4: II:1 T3: 8 T4: 39 Site (n) B(3), FOM(14), G(6), P(2), T(26) T(I:12, II:18), FOM(I:5, II:6) T(47) T(39) B(I:27, II:8, III:14), A(II:7,III:22), FOM(I:33, II:26, III:17), T(I:63,II:3, III:4) B(38), gum(24), T(87), FOM(69), other(12) T(36): tip (I:1, II:2), lateral border(I:6, II:8), tip with lateral border(I:2, II:10), lateral border with FOM(I:1, II:6) RMT(II:4), lip(II:1), T(I:13, II:1), hard P(I:1), FOM(I:1, II:3) FOM(23), G(16), other(8) Age mean (SD) (range) in y Med. 55 (22-75) Med. 53.6 (22-65) I:82% <50 II:63% <50 58.4 (44-72) 64.4 (32-78) 61 (SD 13), 41% 65+ I:37% 65+ II:43% 65+ III:47% 65+ 50% <55 40% 55-64 28% 65-74 13% 75+ Med. 43 (24-66) I:62.6 (10) II:62.2 (9.3) 61.8 (±8.4) n (%male) 51 (80) 41 (83) I:17 (100) II:24 (71) 47 (72) I:5, II:24 III:9, IV:9 39 (54) 224 (66) I:123 (63) II:44 (68) III:57 (68) 230(60) 36 (78) I:10 II:26 I:15 (67) II:9 (100) 47 (83) Table 1 (continued) Sub-groups N/A I: PMMF II: RFFF I: RT pre-Tx II: RT post-Tx III:RT pre- & post-Tx IV: no RT N/A I: nil II: rim res. III: segment res. N/A I: surgery II: adj. therapy I: sentinel lymph node biopsy II: cervical ND level I-III N/A Type C, R C, P C, P C, R L L, P C, R C C Location CHN CHN CHN US UK UK IN BR BR Author 10. W. Li et al. (2013) 11. W. Li et al. (2016) 12. X. Li et al. (2016) 13. Ochoa et al. (2020) 14. Rogers et al. (2004) 15. Rogers et al. (2020) 16. Sakthivel et al. (2017) 17. Seferin et al. (2020) 18. Soares et al. (2018)

RkJQdWJsaXNoZXIy MjY0ODMw